- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05147220
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study CLOU064C12301 consists of an initial Core Part (CP) (maximum duration per participant of up to 30 months), followed by an Extension Part (EP, of up to 5 years duration) for eligible participants.
The Core Part is a randomized, double-blind, double-dummy, active comparator-controlled, fixed-dose, parallel-group, multi-center study in approximately 800 participants with relapsing multiple sclerosis (RMS).
The Extension Part is an open-label, single-arm, fixed-dose design in which eligible participants are treated with remibrutinib for up to 5 years.
A second study of identical design (CLOU064C12302) will be conducted simultaneously. Both studies will be conducted globally and data from the two studies will be pooled for some of the endpoints.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Novartis Pharmaceuticals
- Phone Number: 1-888-669-6682
- Email: novartis.email@novartis.com
Study Contact Backup
- Name: Novartis Pharmaceuticals
- Phone Number: +41613241111
Study Locations
-
-
-
Buenos Aires, Argentina, C1012AAR
- Recruiting
- Novartis Investigative Site
-
Caba, Argentina, C1424BYD
- Recruiting
- Novartis Investigative Site
-
Capital Federal, Argentina, C1023AAB
- Recruiting
- Novartis Investigative Site
-
-
Buenos Aires
-
Caba, Buenos Aires, Argentina, C1122AAK
- Recruiting
- Novartis Investigative Site
-
Capital Federal, Buenos Aires, Argentina, 1424
- Recruiting
- Novartis Investigative Site
-
-
Santa Fe
-
Rosario, Santa Fe, Argentina, 2000
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Antwerpen, Belgium, 2018
- Recruiting
- Novartis Investigative Site
-
Ath, Belgium, 7800
- Recruiting
- Novartis Investigative Site
-
Brasschaat, Belgium, 2930
- Recruiting
- Novartis Investigative Site
-
Brugge, Belgium, 8000
- Recruiting
- Novartis Investigative Site
-
Lier, Belgium, 2500
- Recruiting
- Novartis Investigative Site
-
Melsbroek, Belgium, 1820
- Recruiting
- Novartis Investigative Site
-
Pelt, Belgium, 3900
- Recruiting
- Novartis Investigative Site
-
-
Antwerpen
-
Edegem, Antwerpen, Belgium, 2650
- Recruiting
- Novartis Investigative Site
-
-
Brussel
-
Jette, Brussel, Belgium, 1090
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Pleven, Bulgaria, 5800
- Recruiting
- Novartis Investigative Site
-
Sofia, Bulgaria, 1431
- Recruiting
- Novartis Investigative Site
-
Sofia, Bulgaria, 1113
- Recruiting
- Novartis Investigative Site
-
-
-
-
Region Metropolitana
-
Santiago, Region Metropolitana, Chile, 7650568
- Recruiting
- Novartis Investigative Site
-
Santiago, Region Metropolitana, Chile, 8431657
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Beijing, China, 100730
- Recruiting
- Novartis Investigative Site
-
Beijing, China, 100029
- Recruiting
- Novartis Investigative Site
-
Chongqing, China, 400016
- Recruiting
- Novartis Investigative Site
-
Tianjin, China, 300052
- Recruiting
- Novartis Investigative Site
-
-
Beijing
-
Beijing, Beijing, China, 100000
- Recruiting
- Novartis Investigative Site
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- Recruiting
- Novartis Investigative Site
-
Guangzhou City, Guangdong, China, 510000
- Recruiting
- Novartis Investigative Site
-
-
Henan
-
Zhengzhou, Henan, China, 450052
- Recruiting
- Novartis Investigative Site
-
-
Hunan
-
Changsha, Hunan, China, 410008
- Recruiting
- Novartis Investigative Site
-
-
Inner Mongolia
-
Baotou, Inner Mongolia, China, 014040
- Recruiting
- Novartis Investigative Site
-
Hohhot, Inner Mongolia, China, 010017
- Recruiting
- Novartis Investigative Site
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330006
- Recruiting
- Novartis Investigative Site
-
-
Jilin
-
Changchun, Jilin, China, 130021
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Bogota, Colombia, 110110
- Recruiting
- Novartis Investigative Site
-
-
Atlantico
-
Puerto Colombia, Atlantico, Colombia, 080012
- Recruiting
- Novartis Investigative Site
-
-
Valle Del Cauca
-
Cali, Valle Del Cauca, Colombia, 760012
- Recruiting
- Novartis Investigative Site
-
Cali, Valle Del Cauca, Colombia, 760001
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Osijek, Croatia, 31000
- Recruiting
- Novartis Investigative Site
-
Zadar, Croatia, 23000
- Recruiting
- Novartis Investigative Site
-
Zagreb, Croatia, 10000
- Recruiting
- Novartis Investigative Site
-
-
HRV
-
Rijeka, HRV, Croatia, 51000
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Slagelse, Denmark, DK-4200
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Guatemala, Guatemala, 01015
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Sha Tin, Hong Kong
- Recruiting
- Novartis Investigative Site
-
-
-
-
Delhi
-
New Delhi, Delhi, India, 110017
- Recruiting
- Novartis Investigative Site
-
-
Maharashtra
-
Mumbai, Maharashtra, India, 400008
- Recruiting
- Novartis Investigative Site
-
Nashik, Maharashtra, India, 422005
- Recruiting
- Novartis Investigative Site
-
-
Punjab
-
Chandigarh, Punjab, India, 160012
- Recruiting
- Novartis Investigative Site
-
Ludhiana, Punjab, India, 141008
- Recruiting
- Novartis Investigative Site
-
-
Telangana
-
Hyderabad, Telangana, India, 500082
- Recruiting
- Novartis Investigative Site
-
-
Uttar Pradesh
-
Lucknow, Uttar Pradesh, India, 226014
- Recruiting
- Novartis Investigative Site
-
-
Uttarakhand
-
DehraDun, Uttarakhand, India, 248001
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Dublin, Ireland, DUBLIN 8
- Recruiting
- Novartis Investigative Site
-
Dublin 4, Ireland, DO4
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Napoli, Italy, 80131
- Recruiting
- Novartis Investigative Site
-
-
BS
-
Montichiari, BS, Italy, 25018
- Recruiting
- Novartis Investigative Site
-
-
MI
-
Milano, MI, Italy, 20132
- Recruiting
- Novartis Investigative Site
-
-
RM
-
Roma, RM, Italy, 00133
- Recruiting
- Novartis Investigative Site
-
Roma, RM, Italy, 00168
- Recruiting
- Novartis Investigative Site
-
-
VR
-
Verona, VR, Italy, 37134
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Riga, Latvia, LV 1002
- Recruiting
- Novartis Investigative Site
-
-
LV
-
Riga, LV, Latvia, LV-1005
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Beirut, Lebanon, 6301
- Recruiting
- Novartis Investigative Site
-
-
LBN
-
El Chouf, LBN, Lebanon, 1503201002
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Kuala Lumpur, Malaysia, 50589
- Recruiting
- Novartis Investigative Site
-
-
Pulau Pinang
-
Seberang Jaya, Pulau Pinang, Malaysia, 13700
- Recruiting
- Novartis Investigative Site
-
-
Terengganu
-
Kuala Terengganu, Terengganu, Malaysia, 20400
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Breda, Netherlands, 4818 CK
- Recruiting
- Novartis Investigative Site
-
Hertogenbosch, Netherlands, 5200
- Recruiting
- Novartis Investigative Site
-
Rotterdam, Netherlands, 3079 DZ
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Kielce, Poland, 25 726
- Recruiting
- Novartis Investigative Site
-
Lodz, Poland, 90 324
- Recruiting
- Novartis Investigative Site
-
Lodz, Poland, 93-113
- Recruiting
- Novartis Investigative Site
-
Piotrkow Trybunalski, Poland, 97300
- Recruiting
- Novartis Investigative Site
-
Poznan, Poland, 60-693
- Recruiting
- Novartis Investigative Site
-
Rzeszow, Poland, 35-323
- Recruiting
- Novartis Investigative Site
-
Szczecin, Poland, 70111
- Recruiting
- Novartis Investigative Site
-
-
Dolnoslaskie
-
Wroclaw, Dolnoslaskie, Poland, 52 416
- Recruiting
- Novartis Investigative Site
-
-
Woj Kujawsko-pomorskie
-
Bydgoszcz, Woj Kujawsko-pomorskie, Poland, 85-796
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Bratislava, Slovakia, 82606
- Recruiting
- Novartis Investigative Site
-
Nitra, Slovakia, 94901
- Recruiting
- Novartis Investigative Site
-
Trnava, Slovakia, 917 75
- Recruiting
- Novartis Investigative Site
-
-
Slovak Republic
-
Kosice, Slovak Republic, Slovakia, 04066
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Barcelona, Spain, 08035
- Recruiting
- Novartis Investigative Site
-
Las Palmas de Gran Canaria, Spain, 35010
- Recruiting
- Novartis Investigative Site
-
Leon, Spain, 24080
- Recruiting
- Novartis Investigative Site
-
Madrid, Spain, 28034
- Recruiting
- Novartis Investigative Site
-
Madrid, Spain, 28040
- Recruiting
- Novartis Investigative Site
-
Madrid, Spain, 28222
- Recruiting
- Novartis Investigative Site
-
-
Andalucia
-
Cadiz, Andalucia, Spain, 11009
- Recruiting
- Novartis Investigative Site
-
Cordoba, Andalucia, Spain, 14004
- Recruiting
- Novartis Investigative Site
-
Malaga, Andalucia, Spain, 29010
- Recruiting
- Novartis Investigative Site
-
-
Barcelona
-
Sant Joan Despi, Barcelona, Spain, 08970
- Recruiting
- Novartis Investigative Site
-
-
Cataluna
-
Salt, Cataluna, Spain, 17190
- Recruiting
- Novartis Investigative Site
-
-
Galicia
-
La Coruna, Galicia, Spain, 15006
- Recruiting
- Novartis Investigative Site
-
-
Madrid
-
Alcorcon, Madrid, Spain, 28922
- Recruiting
- Novartis Investigative Site
-
Getafe, Madrid, Spain, 28905
- Recruiting
- Novartis Investigative Site
-
-
Murcia
-
El Palmar, Murcia, Spain, 30120
- Recruiting
- Novartis Investigative Site
-
-
Vizcaya
-
Baracaldo, Vizcaya, Spain, 48903
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Basel, Switzerland, 4031
- Recruiting
- Novartis Investigative Site
-
Bern, Switzerland, 3010
- Recruiting
- Novartis Investigative Site
-
-
-
-
Bristol
-
Westbruy On Trym, Bristol, United Kingdom, BS10 5NB
- Recruiting
- Novartis Investigative Site
-
-
Hampshire
-
Winchester, Hampshire, United Kingdom, SO21 1HU
- Recruiting
- Novartis Investigative Site
-
-
-
-
Arizona
-
Scottsdale, Arizona, United States, 85258
- Recruiting
- Novartis Investigative Site
-
Tucson, Arizona, United States, 85718
- Recruiting
- Novartis Investigative Site
-
-
Arkansas
-
Fort Smith, Arkansas, United States, 72916
- Recruiting
- Novartis Investigative Site
-
-
California
-
Berkeley, California, United States, 94705
- Recruiting
- Novartis Investigative Site
-
Chula Vista, California, United States, 91910
- Recruiting
- Novartis Investigative Site
-
Fullerton, California, United States, 92835
- Recruiting
- Novartis Investigative Site
-
Glendale, California, United States, 91206
- Recruiting
- Novartis Investigative Site
-
Newport Beach, California, United States, 92663
- Recruiting
- Novartis Investigative Site
-
-
Colorado
-
Basalt, Colorado, United States, 81621
- Recruiting
- Novartis Investigative Site
-
Boulder, Colorado, United States, 80301
- Recruiting
- Novartis Investigative Site
-
-
Delaware
-
Newark, Delaware, United States, 19713
- Recruiting
- Novartis Investigative Site
-
-
Florida
-
Altamonte Springs, Florida, United States, 32714
- Recruiting
- Novartis Investigative Site
-
Miami, Florida, United States, 33032
- Recruiting
- Novartis Investigative Site
-
Miami, Florida, United States, 33175
- Recruiting
- Novartis Investigative Site
-
Orlando, Florida, United States, 32806
- Recruiting
- Novartis Investigative Site
-
Orlando, Florida, United States, 32825
- Recruiting
- Novartis Investigative Site
-
Ormond Beach, Florida, United States, 32174
- Recruiting
- Novartis Investigative Site
-
Port Charlotte, Florida, United States, 33952
- Recruiting
- Novartis Investigative Site
-
Seminole, Florida, United States, 33777
- Recruiting
- Novartis Investigative Site
-
Tampa, Florida, United States, 33612
- Recruiting
- Novartis Investigative Site
-
Tampa, Florida, United States, 33609
- Recruiting
- Novartis Investigative Site
-
-
Georgia
-
Savannah, Georgia, United States, 31406
- Recruiting
- Novartis Investigative Site
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96817
- Withdrawn
- Novartis Investigative Site
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Recruiting
- Novartis Investigative Site
-
Chicago, Illinois, United States, 60616
- Recruiting
- Novartis Investigative Site
-
Park Ridge, Illinois, United States, 60068
- Recruiting
- Novartis Investigative Site
-
-
Indiana
-
Fort Wayne, Indiana, United States, 46845
- Recruiting
- Novartis Investigative Site
-
-
Kansas
-
Overland Park, Kansas, United States, 66210
- Recruiting
- Novartis Investigative Site
-
-
Maryland
-
Bethesda, Maryland, United States, 20817
- Recruiting
- Novartis Investigative Site
-
Lutherville, Maryland, United States, 21093
- Recruiting
- Novartis Investigative Site
-
-
Massachusetts
-
Foxboro, Massachusetts, United States, 02035
- Recruiting
- Novartis Investigative Site
-
-
Missouri
-
Saint Louis, Missouri, United States, 63131
- Recruiting
- Novartis Investigative Site
-
-
Montana
-
Billings, Montana, United States, 59101
- Recruiting
- Novartis Investigative Site
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
- Recruiting
- Novartis Investigative Site
-
Raleigh, North Carolina, United States, 27607
- Recruiting
- Novartis Investigative Site
-
-
Ohio
-
Westerville, Ohio, United States, 43082
- Completed
- Novartis Investigative Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Recruiting
- Novartis Investigative Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107-5098
- Recruiting
- Novartis Investigative Site
-
Reading, Pennsylvania, United States, 19611
- Recruiting
- Novartis Investigative Site
-
-
South Carolina
-
Summerville, South Carolina, United States, 29485
- Recruiting
- Novartis Investigative Site
-
-
Texas
-
Dallas, Texas, United States, 75206
- Recruiting
- Novartis Investigative Site
-
Dallas, Texas, United States, 75390-9034
- Withdrawn
- Novartis Investigative Site
-
El Paso, Texas, United States, 79912
- Withdrawn
- Novartis Investigative Site
-
Houston, Texas, United States, 77074
- Recruiting
- Novartis Investigative Site
-
McAllen, Texas, United States, 78503
- Recruiting
- Novartis Investigative Site
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- Withdrawn
- Novartis Investigative Site
-
-
Virginia
-
Vienna, Virginia, United States, 22182
- Recruiting
- Novartis Investigative Site
-
-
Washington
-
Seattle, Washington, United States, 98122
- Recruiting
- Novartis Investigative Site
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- Recruiting
- Novartis Investigative Site
-
Neenah, Wisconsin, United States, 54956
- Recruiting
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 to 55 years of age
- Diagnosis of RMS according to the 2017 McDonald diagnostic criteria
- At least: 1 documented relapse within the previous year. OR 2 documented relapses within the previous 2 years, OR 1 active Gadolinium (Gd)-enhancing lesion in the 12 months.
- EDSS score of 0 to 5.5 (inclusive)
- Neurologically stable within 1 month
Exclusion Criteria:
- Diagnosis of primary progressive multiple sclerosis (PPMS)
- Disease duration of more than 10 years in participants with EDSS score of 2 or less at screening
- History of clinically significant CNS disease other than MS
- Ongoing substance abuse (drug or alcohol)
- History of malignancy of any organ system (other than complete resection of localized basal cell carcinoma of the skin or in situ cervical cancer),
- Participants with history of confirmed Progressive Multifocal Leukoencephalopathy (PML) or Neurological symptoms consistent with PML
- suicidal ideation or behavior
- Evidence of clinically significant cardiovascular, neurological, psychiatric, pulmonary , renal, hepatic, endocrine, metabolic, hematological disorders or gastrointestinal disease that can interfere with interpretation of the study results or protocol adherence
- Participants who have had a splenectomy
- Active clinically significant systemic bacterial, viral, parasitic or fungal infections
- Positive results for syphilis or tuberculosis testing
- Uncontrolled disease states, such as asthma, or inflammatory bowel disease, where flares are commonly treated with oral or parenteral corticosteroids
- Active, chronic disease of the immune system (including stable disease treated with immune therapy (e.g. Leflunomide, Methotrexate)) other than MS (e.g. rheumatoid arthritis, systemic lupus erythematosus, etc.) with the exception of well-controlled diabetes or thyroid disorder.
- Participants with a known immunodeficiency syndrome (AIDS, hereditary immune deficiency, drug induced immune deficiency), or tested positive for HIV antibody
- History or current treatment for hepatic disease including but not limited to acute or chronic hepatitis, cirrhosis or hepatic failure or participants with moderate or severe hepatic impairment (Child-Pugh class C) or any chronic liver or biliary disease.
- History of severe renal disease or creatinine level
- Participants at risk of developing or having reactivation of hepatitis
Hematology parameters at screening:
- Hemoglobin: < 10 g/dl (<100g/L)
- Platelets: < 100000/mm3 (<100 x 109/L)
- Absolute lymphocyte count < 800/mm3 (<0.8 x 109/L)
- White blood cells: <3 000/mm3 (<3.0 x 109/L)
- Neutrophils: < 1 500/mm3 (<1.5 x 109/L)
- B-cell count < 50% lower limit of normal (LLN) or total IgG & total IgM < LLN (only required for participants who had a history of receiving B-cell therapies, such as rituximab, ocrelizumab or ofatumumab, prior to screening)
- History or current diagnosis of significant ECG abnormalities
- Resting QTcF ≥450 msec (male) or ≥460 msec (female) at pre-treatment (prior to randomization)
- Use of other investigational drugs
- Requirement for anticoagulant medication or use of dual anti-platelet therapy Significant bleeding risk or coagulation disorders,
- History of gastrointestinal bleeding
- Major surgery within 8 weeks prior to screening
- History of hypersensitivity to any of the study drugs or excipients
- Pregnant or nursing (lactating) female participants, prior to randomization
- Women of childbearing potential not using highly effective contraception
- Sexually active males not agreeing to use condom
- Have received any live or live-attenuated vaccines within 6 weeks of randomization or requirement to receive these vaccinations during study
- Use of strong CYP3A4 inhibitors or strong CYP3A4 inducers within two weeks prior to randomization
Inclusion to Extension part:
• patient who complete the Core Part of the study on double-blind study treatment and conduct the Accelerated Elimination Procedure (AEP)
Other inclusion and exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Remibrutinib - Core
Remibrutinib tablet and matching placebo of teriflunomide capsule
|
tablet taken orally
Other Names:
|
Active Comparator: Teriflunomide - Core
Teriflunomide capsule and matching placebo remibrutinib tablet
|
capsule taken orally
|
Experimental: Remibrutinib - Extension
Participants on remibrutinib in Core will continue on remibrutinib tablet
|
tablet taken orally
Other Names:
|
Experimental: Remibrutinib - Extension (on teriflunomide in Core)
Participants on teriflunomide in Core will switch to remibrutinib tablet
|
tablet taken orally
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Annualized relapse rate (ARR) of confirmed relapses [Core Part]
Time Frame: From Baseline, up to 30 month
|
ARR is the average number of confirmed MS relapses in a year
|
From Baseline, up to 30 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to 3-month confirmed disability progression (3mCDP) on Expanded Disability Status Scale (EDSS) [Core Part] (pooled data)
Time Frame: Baseline up to 30 month
|
Time to 3-month confirmed disability progression (3mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 3 months
|
Baseline up to 30 month
|
Time to 6-month confirmed disability progression (6mCDP) on EDSS [Core Part] (pooled data)
Time Frame: Baseline up to 30 month
|
Time to 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 6 months
|
Baseline up to 30 month
|
Annualized rate of new or enlarging T2 lesion [Core Part]
Time Frame: Baseline up to 30 month
|
Number of new/newly enlarged T2 lesions per year
|
Baseline up to 30 month
|
Neurofilament light chain (Nfl) [Core Part]
Time Frame: Baseline up to 30 months
|
Neurofilament light chain (NfL) concentration in serum
|
Baseline up to 30 months
|
Number of Gd-enhancing T1 lesions per MRI scan [Core Part]
Time Frame: Baseline up to 30 month
|
Average number of Gd-enhancing T1 lesions per scan
|
Baseline up to 30 month
|
Percentage of participants with No Evidence of Disease Activity-3 (NEDA-3) [Core Part] (pooled data)
Time Frame: Baseline up to 30 month
|
Percentage of participants with No Evidence of Disease Activity-3 (NEDA-3), as assessed by absence of confirmed MS relapses, 6mCDP and new/enlarging T2 lesions on MRI
|
Baseline up to 30 month
|
Time to first confirmed relapse [Core Part]
Time Frame: Baseline up to 30 month
|
Change in the Expanded Disability Status Scale (EDSS), an increase of at least 0.5 points on the EDSS (total) score, or an increase of at least 1 point on at least two functional scores (FSs), or an increase of at least 2 points on at least one FS, excluding changes involving bowel/bladder or cerebral FS, compared to the previous available rating.
|
Baseline up to 30 month
|
Time to 6-month confirmed disability improvement (6mCDI) on EDSS [Core Part] (pooled data)
Time Frame: Baseline up to 30 month
|
Decrease in Expanded Disability Status Scale Score (EDSS) which is sustained for at least 6 months
|
Baseline up to 30 month
|
Change from baseline in the Symbol Digit Modalities Test (SDMT) [Core Part] (pooled data)
Time Frame: Baseline up to 30 month
|
Symbol Digit Modalities Test (SDMT), an array of symbols paired with empty spaces, measures processing in speed; participants verbally match the number for each symbol as rapidly as possible.
The score is the number of correctly coded items in 90 seconds.
Higher scores indicate improvement.
Lower scores indicate worsening
|
Baseline up to 30 month
|
Time to 6-month confirmed worsening by at least 20% in the Timed 25-foot walk test (T25FW) [Core Part] (pooled data)
Time Frame: Baseline, up to 30 month
|
The patient walking speed to cover 25 foot distance is recorded in seconds.
Longer time indicates poorer lower limb function.
20% worsening is defined as 20% increase from baseline T25FW score
|
Baseline, up to 30 month
|
Time to 6-month confirmed worsening by at least 20% in the Timed 9-hole peg test (9HPT) (pooled data) [Core Part] (pooled data)
Time Frame: Baseline up to 30 month
|
The patient's right and left arm function to peg 9 holes measured in seconds.
Longer time indicates poorer upper limb function.
20% worsening is defined as 20% increase from baseline 9HPT score in at least one hand (average of two trials per hand)
|
Baseline up to 30 month
|
Time to composite 6-month confirmed disability Progression (CDP) [Core Part] (pooled data)
Time Frame: Baseline up to 30 month
|
The composite involves CDP and worsening by at least 20% in T25FW and 9HPT
|
Baseline up to 30 month
|
Change from Baseline in T2 lesion volume [Core Part]
Time Frame: Baseline up to 30 month
|
Change from baseline in total T2 lesion volume.
|
Baseline up to 30 month
|
Change from baseline in Fatigue Symptoms and Impacts Questionnaire - Relapsing Multiple Sclerosis (FSIQ-RMS) [Core Part]
Time Frame: Baseline up to 30 month
|
20-item, self-administered questionnaire.
Global score ranges from 0 to 100 where higher score represents greater fatigue
|
Baseline up to 30 month
|
Change from baseline in Generalized Anxiety Disorder Scale (GAD-7) [Core Part]
Time Frame: Baseline up to 30 month
|
7-item, self-administered scale.
It has a global score ranging from 0-21.
Higher score means higher severity of anxiety symptoms
|
Baseline up to 30 month
|
Change from baseline in Patient Health Questionnaire-9 (PHQ-9) [Core Part]
Time Frame: Baseline up to 30 month
|
9-item, self-administered scale.
Scores can range from 0 to 27.
PHQ-9 scores of 5, 10, 15, and 20 represent mild, moderate, moderately severe, and severe depression, respectively
|
Baseline up to 30 month
|
Change from baseline in Brief Pain Inventory- short form (BPI-SF) [Core Part]
Time Frame: Baseline up to 30 month
|
15-item, self-administered questionnaire to assess the severity of pain and the impact of pain on daily functions.
Includes seven-item interference scale.
It has a 10-point response option, ranging from 0 (does not interfere) to 10 (completely interferes).
Global score ranges from 0 to 10, where lower scores represent lower pain
|
Baseline up to 30 month
|
Change from baseline in Health Utilities Index (HUI-Ill) [Core Part]
Time Frame: Baseline up to 30 month
|
15-item, self-administered index that measures eight health-related quality of life areas including vision, hearing, speech, ambulation/mobility, pain, dexterity, emotion, and cognition
|
Baseline up to 30 month
|
Change from baseline in Multiple Sclerosis Impact Scale (MSIS-29) [Core Part]
Time Frame: Baseline up to 30 month
|
29-item, self-administered questionnaire that includes 2 domains, physical and psychological.
Responses are captured on a 4-point scale ranging from "not at all" (1) to "extremely" (4), where higher scores reflect greater impact on day to day life
|
Baseline up to 30 month
|
Number of participants with Adverse events and Serious adverse events(SAE) [Core Part]
Time Frame: Baseline up to 30 month
|
Adverse events and SAEs including clinically significant , laboratory data, vital signs, electrocardiogram (ECG), Columbia Suicide Severity Rating
|
Baseline up to 30 month
|
Pharmacokinetics of remibrutinib [Core Part]
Time Frame: Month 1, Month 6
|
Blood concentrations of remibrutinib
|
Month 1, Month 6
|
Number of participants with Adverse events and Serious adverse events (SAE) [Extension Part]
Time Frame: Day 1 Extension up to 5 years
|
Adverse events and SAEs including clinically significant, laboratory data, vital signs, electrocardiogram (ECG), Columbia Suicide Severity Rating
|
Day 1 Extension up to 5 years
|
Annualized relapse rate (ARR) of confirmed relapses [Extension Part]
Time Frame: Day 1 Extension up to 5 years
|
ARR is the average number of confirmed MS relapses in a year
|
Day 1 Extension up to 5 years
|
Annualized rate of new or enlarging T2 lesion [Extension Part]
Time Frame: Day 1 Extension up to 5 years
|
Number of new/newly enlarged T2 lesions per year
|
Day 1 Extension up to 5 years
|
Time to 6-month confirmed disability progression (6mCDP) on EDSS [Extension Part]
Time Frame: Day 1 Extension up to 5 years
|
Time to 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 6 months
|
Day 1 Extension up to 5 years
|
Change from baseline in the Symbol Digit Modalities Test (SDMT) [Extension Part]
Time Frame: Day 1 Extension up to 5 years
|
Symbol Digit Modalities Test (SDMT), an array of symbols paired with empty spaces, measures processing in speed; participants verbally match the number for each symbol as rapidly as possible.
The score is the number of correctly coded items in 90 seconds.
Higher scores indicate improvement.
Lower scores indicate worsening
|
Day 1 Extension up to 5 years
|
Neurofilament light chain (NfL) [Extension Part]
Time Frame: Day 1 Extension up to 5 years
|
Neurofilament light chain (NfL) concentration in serum
|
Day 1 Extension up to 5 years
|
Change from baseline in Fatigue Symptoms and Impacts Questionnaire - Relapsing Multiple Sclerosis (FSIQ-RMS) [Extension Part]
Time Frame: Day 1 Extension up to 5 years
|
20-item, self-administered questionnaire.
Global score ranges from 0 to 100 where higher score represents greater fatigue
|
Day 1 Extension up to 5 years
|
Change from baseline in Generalized Anxiety Disorder Scale (GAD-7) [Extension Part]
Time Frame: Day 1 Extension up to 5 years
|
7-item, self-administered scale.
It has a global score ranging from 0-21.
Higher score means higher severity of anxiety symptoms
|
Day 1 Extension up to 5 years
|
Change from baseline in Patient Health Questionnaire-9 (PHQ-9) [Extension Part]
Time Frame: Day 1 Extension up to 5 years
|
9-item, self-administered scale.
Scores can range from 0 to 27.
PHQ-9 scores of 5, 10, 15, and 20 represent mild, moderate, moderately severe, and severe depression, respectively
|
Day 1 Extension up to 5 years
|
Change from baseline in Brief Pain Inventory- short form (BPI-SF) [Extension Part]
Time Frame: Day 1 Extension up to 5 years
|
15-item, self-administered questionnaire to assess the severity of pain and the impact of pain on daily functions.
Includes seven-item interference scale.
It has a 10-point response option, ranging from 0 (does not interfere) to 10 (completely interferes).
Global score ranges from 0 to 10, where lower scores represent lower pain
|
Day 1 Extension up to 5 years
|
Change from baseline in Health Utilities Index (HUI-Ill) [Extension Part]
Time Frame: Day 1 Extension up to 5 years
|
15-item, self-administered index that measures eight health-related quality of life areas including vision, hearing, speech, ambulation/mobility, pain, dexterity, emotion, and cognition
|
Day 1 Extension up to 5 years
|
Change from baseline in Multiple Sclerosis Impact Scale (MSIS-29) [Extension Part]
Time Frame: Day 1 Extension up to 5 years
|
29-item, self-administered questionnaire that includes 2 domains, physical and psychological.
Responses are captured on a 4-point scale ranging from "not at all" (1) to "extremely" (4), where higher scores reflect greater impact on day to day life
|
Day 1 Extension up to 5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Multiple Sclerosis
- Sclerosis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Protein Kinase Inhibitors
- Teriflunomide
- Remibrutinib
Other Study ID Numbers
- CLOU064C12301
- 2020-005899-36 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsing Multiple Sclerosis
-
BiogenWithdrawnRelapsing-Remitting Multiple Sclerosis | Relapsing Forms of Multiple Sclerosis
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenAbbVieTerminatedMultiple Sclerosis | Relapsing-Remitting Multiple SclerosisUnited States, Denmark, Italy, United Kingdom, Czechia, Canada, Hungary, Spain, Australia, Israel, Georgia, Serbia, Russian Federation, Ukraine, India, Poland, Brazil, France, Argentina, Germany, Greece, Ireland, Mexico, Moldova, Republic... and more
-
EMD SeronoPfizerCompletedRelapsing-remitting Multiple SclerosisUnited States, United Kingdom, Argentina, Austria, Brazil, France, Germany, Italy, Netherlands, Russian Federation, Spain, Switzerland
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedRelapsing-Remitting Multiple SclerosisUnited States
-
BiogenTerminatedRelapsing-Remitting Multiple SclerosisUnited States, Spain, Germany, Australia, Sweden, Czechia, France, Italy, United Kingdom
-
Novartis PharmaceuticalsWithdrawnMultiple Sclerosis (Relapsing Remitting)
-
Genzyme, a Sanofi CompanyTerminatedRelapsing-remitting Multiple SclerosisSweden, Poland, Russian Federation, United States, Canada
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple SclerosisGermany
Clinical Trials on Remibrutinib
-
Novartis PharmaceuticalsTerminatedSjögren SyndromeSpain, United States, Belgium, Hungary, Germany, Switzerland, Australia, Denmark, China, Taiwan, United Kingdom, Bulgaria
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsCompletedChronic Spontaneous UrticariaHungary, Taiwan, Italy, Korea, Republic of, Australia, France, Bulgaria, Czechia, Turkey, India, United States, Argentina, Mexico, Spain, Japan, Colombia, Russian Federation, Singapore, Puerto Rico
-
Novartis PharmaceuticalsActive, not recruitingChronic Spontaneous UrticariaSpain, Germany, France, Korea, Republic of, Turkey, Argentina, Slovakia, United States, Canada, Singapore
-
Novartis PharmaceuticalsCompletedChronic Spontaneous UrticariaJapan
-
Novartis PharmaceuticalsRecruitingChronic Spontaneous UrticariaUnited States, Singapore, Spain, Germany, Turkey, Italy, Hong Kong, China, Malaysia, Argentina, Thailand, Poland, Japan, Netherlands, Chile, Canada
-
Novartis PharmaceuticalsRecruitingAllergy, PeanutUnited States, Spain
-
Novartis PharmaceuticalsRecruitingChronic Spontaneous UrticariaUnited States, Korea, Republic of, Spain, France, Germany, Italy, United Kingdom, China, Argentina, Hungary, Czechia, Turkey, Bulgaria, Colombia, Denmark, Japan, Russian Federation, Slovakia, Taiwan, Australia, Singapore, Switzerland and more
-
Novartis PharmaceuticalsCompletedChronic Spontaneous UrticariaUnited States, India, Malaysia, Taiwan, Poland, United Kingdom, China, Thailand, Switzerland, Germany, Vietnam, Brazil, Russian Federation, Slovakia, Denmark, Canada, South Africa, Austria
-
Novartis PharmaceuticalsAvailableChronic Spontaneous Urticaria